-+ 0.00%
-+ 0.00%
-+ 0.00%

Praxis Precision Medicines forecasts $10 billion in peak sales for ulixacaltamide

PUBT·11/12/2026 21:44:53
Listen to the news
Praxis Precision Medicines forecasts $10 billion in peak sales for ulixacaltamide
  • Praxis Precision Medicines outlined more than $20 billion in potential peak sales from its sales guidance and pipeline.
  • Ulixacaltamide peak sales guidance stands at $10 billion; an estimated 9 million Americans live with essential tremor.
  • Relutrigine peak sales guidance is $5 billion, compared with $4 billion for vormatrigine.
  • Elsunersen peak sales guidance is $1 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.